keyword
MENU ▼
Read by QxMD icon Read
search

pet dementia

keyword
https://www.readbyqxmd.com/read/28653036/assessment-of-amyloid-%C3%AE-in-pathologically-confirmed-frontotemporal-dementia-syndromes
#1
Rachel H Tan, Jillian J Kril, Yue Yang, Nicole Tom, John R Hodges, Victor L Villemagne, Christopher C Rowe, Cristian E Leyton, John B J Kwok, Lars M Ittner, Glenda M Halliday
INTRODUCTION: The diagnostic utility of in vivo amyloid β (Aβ) imaging to aid in the clinical distinction between frontotemporal dementia (FTD) and Alzheimer's disease remains unclear without data on the prevalence and severity of Aβ in pathologically confirmed FTD syndromes. METHODS: Aβ was assessed in 98 autopsy-confirmed FTD and 36 control cases, and the pathological accuracy of (11)C-Pittsburgh compound B (PiB)-positron emission tomography imaging was assessed in a subset of FTD cases (n = 15)...
2017: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
https://www.readbyqxmd.com/read/28642699/cerebral-blood-flow-and-amyloid-%C3%AE-interact-to-affect-memory-performance-in-cognitively-normal-older-adults
#2
Katherine J Bangen, Alexandra L Clark, Emily C Edmonds, Nicole D Evangelista, Madeleine L Werhane, Kelsey R Thomas, Lyzette E Locano, My Tran, Zvinka Z Zlatar, Daniel A Nation, Mark W Bondi, Lisa Delano-Wood
Cerebral blood flow (CBF) alterations and amyloid-β (Aβ) accumulation have been independently linked to cognitive deficits in older adults at risk for dementia. Less is known about how CBF and Aβ may interact to affect cognition in cognitively normal older adults. Therefore, we examined potential statistical interactions between CBF and Aβ status in regions typically affected in Alzheimer's disease (AD) within a sample of older adults from the Alzheimer's Disease Neuroimaging Initiative (ADNI) study. Sixty-two cognitively normal participants (mean age = 72 years) underwent neuroimaging and memory testing...
2017: Frontiers in Aging Neuroscience
https://www.readbyqxmd.com/read/28632523/frontotemporal-dementia-presenting-as-gambling-disorder-when-a-psychiatric-condition-is-the-clue-to-a-neurodegenerative-disease
#3
Giacomo Tondo, Fabiola De Marchi, Emanuela Terazzi, Marta Sacchetti, Roberto Cantello
Behavioral variant frontotemporal dementia, the most common form of frontotemporal dementia, is characterized by executive dysfunction and changes in personality and behavior, sometimes with associated psychiatric disorders. We report a man who suddenly developed a gambling disorder when he was 55 years old. A year later he developed personality changes of agitation, euphoria, and disinhibition, along with binge eating and dysthymia. He did not improve on paroxetine 40 mg/day. Two years after the onset of his symptoms, he came to our clinic for evaluation...
June 2017: Cognitive and Behavioral Neurology: Official Journal of the Society for Behavioral and Cognitive Neurology
https://www.readbyqxmd.com/read/28616381/anosognosia-for-memory-deficits-in-mild-cognitive-impairment-insight-into-the-neural-mechanism-using-functional-and-molecular-imaging
#4
Patrizia Vannini, Bernard Hanseeuw, Catherine E Munro, Rebecca E Amariglio, Gad A Marshall, Dorene M Rentz, Alvaro Pascual-Leone, Keith A Johnson, Reisa A Sperling
Anosognosia, or loss of insight of memory deficits, is a common and striking symptom in Alzheimer's disease (AD). Previous findings in AD dementia patients suggest that anosognosia is due to both functional metabolic changes within cortical midline structures involved in self-referential processes, as well as functional disconnection between these regions. The present study aims to extend these findings by investigating the neural correlates of anosognosia in the prodromal stage of AD. Here, we used regional brain metabolism (resting state 18-F fluorodeoxyglucose positron emission tomography (FDG-PET)) to unravel the metabolic correlates of anosognosia in subjects with amnestic mild cognitive impairment (aMCI) and subsequently resting state functional magnetic resonance imaging (rs-fMRI) to investigate the intrinsic connectivity disruption between brain regions...
2017: NeuroImage: Clinical
https://www.readbyqxmd.com/read/28612291/-f-18-av-1451-binding-correlates-with-postmortem-neurofibrillary-tangle-braak-staging
#5
Marta Marquié, Michael Siao Tick Chong, Alejandro Antón-Fernández, Eline E Verwer, Nil Sáez-Calveras, Avery C Meltzer, Prianca Ramanan, Ana C Amaral, Jose Gonzalez, Marc D Normandin, Matthew P Frosch, Teresa Gómez-Isla
[F-18]-AV-1451, a PET tracer specifically developed to detect brain neurofibrillary tau pathology, has the potential to facilitate accurate diagnosis of Alzheimer's disease (AD), staging of brain tau burden and monitoring disease progression. Recent PET studies show that patients with mild cognitive impairment and AD dementia exhibit significantly higher in vivo [F-18]-AV-1451 retention than cognitively normal controls. Importantly, PET patterns of [F-18]-AV-1451 correlate well with disease severity and seem to match the predicted topographic Braak staging of neurofibrillary tangles (NFTs) in AD, although this awaits confirmation...
June 13, 2017: Acta Neuropathologica
https://www.readbyqxmd.com/read/28609533/association-between-elevated-brain-amyloid-and-subsequent-cognitive-decline-among-cognitively-normal-persons
#6
Michael C Donohue, Reisa A Sperling, Ronald Petersen, Chung-Kai Sun, Michael W Weiner, Paul S Aisen
Importance: Among cognitively normal individuals, elevated brain amyloid (defined by cerebrospinal fluid assays or positron emission tomography regional summaries) can be related to risk for later Alzheimer-related cognitive decline. Objective: To characterize and quantify the risk for Alzheimer-related cognitive decline among cognitively normal individuals with elevated brain amyloid. Design, Setting, and Participants: Exploratory analyses were conducted with longitudinal cognitive and biomarker data from 445 cognitively normal individuals in the United States and Canada...
June 13, 2017: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/28603769/longitudinal-changes-in-amyloid-positron-emission-tomography-and-volumetric-magnetic-resonance-imaging-in-the-nondemented-down-syndrome-population
#7
Patrick J Lao, Ben L Handen, Tobey J Betthauser, Iulia Mihaila, Sigan L Hartley, Annie D Cohen, Dana L Tudorascu, Peter D Bulova, Brian J Lopresti, Rameshwari V Tumuluru, Dhanabalan Murali, Chester A Mathis, Todd E Barnhart, Charles K Stone, Julie C Price, Darlynne A Devenny, Marsha R Mailick, William E Klunk, Sterling C Johnson, Bradley T Christian
INTRODUCTION: Down syndrome (DS) arises from a triplication of chromosome 21, causing overproduction of the amyloid precursor protein and predisposes individuals to early Alzheimer's disease (AD). METHODS: Fifty-two nondemented adults with DS underwent two cycles of carbon 11-labeled Pittsburgh compound B ([(11)C]PiB) and T1 weighted magnetic resonance imaging (MRI) scans 3.0 ± 0.6 years apart. Standard uptake value ratio (SUVR) images (50-70 minutes; cerebellar gray matter [GM]) and GM volumes were analyzed in standardized space (Montreal Neurological Institute space)...
2017: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
https://www.readbyqxmd.com/read/28601570/agreement-among-neuropsychological-and-behavioral-data-and-pib-findings-in-diagnosing-frontotemporal-dementia
#8
Kelly A Ryan, Dustin Hammers, Angeline DeLeon, Hande Bilen, Kirk Frey, James Burke, Roger Albin, Nancy Barbas, Judith Heidebrink, Bruno Giordani
Diagnostic inaccuracies have been reported in Alzheimer's disease (AD) and Frontotemporal Dementia (FTD) using clinical data alone. The [(11)C]-PiB PET scan offers a new method of identifying AD based on the detection of amyloid deposits. Our study investigated whether there was an agreement between neuropsychological and behavioral data and PiB findings in the diagnosis of FTD. Participants were 32 patients diagnosed with suspected FTD by clinical consensus. All participants underwent neuropsychological testing and PiB imaging...
June 7, 2017: Journal of Clinical Neuroscience: Official Journal of the Neurosurgical Society of Australasia
https://www.readbyqxmd.com/read/28592457/functional-network-integrity-presages-cognitive-decline-in-preclinical-alzheimer-disease
#9
Rachel F Buckley, Aaron P Schultz, Trey Hedden, Kathryn V Papp, Bernard J Hanseeuw, Gad Marshall, Jorge Sepulcre, Emily E Smith, Dorene M Rentz, Keith A Johnson, Reisa A Sperling, Jasmeer P Chhatwal
OBJECTIVE: To examine the utility of resting-state functional connectivity MRI (rs-fcMRI) measurements of network integrity as a predictor of future cognitive decline in preclinical Alzheimer disease (AD). METHODS: A total of 237 clinically normal older adults (aged 63-90 years, Clinical Dementia Rating 0) underwent baseline β-amyloid (Aβ) imaging with Pittsburgh compound B PET and structural and rs-fcMRI. We identified 7 networks for analysis, including 4 cognitive networks (default, salience, dorsal attention, and frontoparietal control) and 3 noncognitive networks (primary visual, extrastriate visual, motor)...
June 7, 2017: Neurology
https://www.readbyqxmd.com/read/28590490/synthesis-resolution-and-in-vitro-evaluation-of-three-vesicular-acetylcholine-transporter-ligands-and-evaluation-of-the-lead-fluorine-18-radioligand-in-a-nonhuman-primate
#10
Xuyi Yue, Hongjun Jin, Hui Liu, Zonghua Luo, Xiang Zhang, Kota Kaneshige, Hubert P Flores, Joel S Perlmutter, Stanley M Parsons, Zhude Tu
The vesicular acetylcholine transporter (VAChT) is a reliable biomarker for assessing cholinergic dysfunction associated with dementia. We recently reported three new potent and selective carbon-11 labeled VAChT radiotracers. Herein, we report the resolution with a Chiralcel OD column of three additional fluorine containing VAChT ligands in which a fluoroethoxy or fluoroethylamino moiety was substituted for the methoxy group. An in vitro competitive binding assay showed that (-)-7 had high potency for VAChT (Ki-VAChT = 0...
June 21, 2017: Organic & Biomolecular Chemistry
https://www.readbyqxmd.com/read/28587897/comparison-of-multiple-tau-pet-measures-as-biomarkers-in-aging-and-alzheimer-s-disease
#11
Anne Maass, Susan Landau, Suzanne L Baker, Andy Horng, Samuel N Lockhart, Renaud La Joie, Gil D Rabinovici, William J Jagust
The recent development of tau-specific positron emission tomography (PET) tracers enables in vivo quantification of regional tau pathology, one of the key lesions in Alzheimer's disease (AD). Tau PET imaging may become a useful biomarker for clinical diagnosis and tracking of disease progression but there is no consensus yet on how tau PET signal is best quantified. The goal of the current study was to evaluate multiple whole-brain and region-specific approaches to detect clinically relevant tau PET signal...
June 3, 2017: NeuroImage
https://www.readbyqxmd.com/read/28579482/precuneus-degeneration-and-isolated-apathy-in-patients-with-parkinson-s-disease
#12
Jung Hwan Shin, Seong A Shin, Jee-Young Lee, Hyunwoo Nam, Jae-Sung Lim, Yu Kyeong Kim
INTRODUCTION: To investigate isolated apathy in a set of consecutively enrolled Parkinson's disease (PD) patients without dementia, depression, and significant motor response fluctuations, by conducting neuropsychological and neuroimaging analyses. METHODS: One hundred twenty-four patients were eligible for inclusion in this study. Clinical information and data were collected from a predefined neuropsychological test battery, including the mini-mental status examination, apathy scale, geriatric depression scale, digit span test, Boston naming test, Seoul verbal learning test, controlled oral word association test, go-no-go test, and the Rey figure copy test...
June 1, 2017: Neuroscience Letters
https://www.readbyqxmd.com/read/28576172/multimodal-pet-imaging-of-amyloid-and-tau-pathology-in-alzheimer-disease-and-non-alzheimer-disease-dementias
#13
REVIEW
Chenjie Xia, Bradford C Dickerson
Biomarkers of the molecular pathology underpinning dementia syndromes are increasingly recognized as crucial for diagnosis and development of disease-modifying treatments. Amyloid PET imaging is an integral part of the diagnostic assessment of Alzheimer disease. Its use has also deepened understanding of the role of amyloid pathology in Lewy body disorders and aging. Tau PET imaging is an imaging biomarker that will likely play an important role in the diagnosis, monitoring, and treatment in dementias. Using tau PET imaging to examine how tau pathology relates to amyloid and other markers of neurodegeneration will serve to better understand the pathophysiologic cascade that leads to dementia...
July 2017: PET Clinics
https://www.readbyqxmd.com/read/28575149/cerebrovascular-resistance-effects-on-cognitive-decline-cortical-atrophy-and-progression-to-dementia
#14
Belinda Yew, Daniel A Nation
Evidence for vascular contributions to Alzheimer's disease has been increasingly identified, with increased blood pressure and decreased cerebral blood flow both linked to in vivo biomarkers and clinical progression of Alzheimer's disease. We therefore hypothesized that an elevated ratio of blood pressure to cerebral blood flow, indicative of cerebrovascular resistance, would exhibit earlier and more widespread associations with Alzheimer's disease than cerebral blood flow alone. Further, we predicted that increased cerebrovascular resistance and amyloid retention would synergistically influence cognitive performance trajectories, independent of neuronal metabolism...
June 1, 2017: Brain: a Journal of Neurology
https://www.readbyqxmd.com/read/28565908/synthesis-and-preliminary-studies-of-a-novel-negative-allosteric-modulator-11-c-qca-for-imaging-of-metabotropic-glutamate-receptor-2
#15
Xiaofei Zhang, Katsushi Kumata, Tomoteru Yamasaki, Ran Cheng, Akiko Hatori, Longle Ma, Yiding Zhang, Lin Xie, Lu Wang, Hye Jin Kang, Douglas J Sheffler, Nicholas D P Cosford, Ming-Rong Zhang, Steven H Liang
Metabotropic glutamate 2 receptors (mGlu2) are involved in the pathogenesis of several CNS disorders and neurodegenerative diseases. Pharmacological modulation of this target represents a potential disease-modifying approach for the treatment of substance abuse, depression, schizophrenia and dementias. While quantification of mGlu2 receptors in the living brain by positron emission tomography (PET) would help us better understand signaling pathways relevant to these conditions, few successful examples have been demonstrated to image mGlu2 in vivo and a suitable PET tracer is yet to be identified...
May 31, 2017: ACS Chemical Neuroscience
https://www.readbyqxmd.com/read/28561534/gender-differences-in-healthy-aging-and-alzheimer-s-dementia-a-18-f-fdg-pet-study-of-brain-and-cognitive-reserve
#16
Maura Malpetti, Tommaso Ballarini, Luca Presotto, Valentina Garibotto, Marco Tettamanti, Daniela Perani
Cognitive reserve (CR) and brain reserve (BR) are protective factors against age-associated cognitive decline and neurodegenerative disorders. Very limited evidence exists about gender effects on brain aging and on the effect of CR on brain modulation in healthy aging and Alzheimer's Dementia (AD). We investigated gender differences in brain metabolic activity and resting-state network connectivity, as measured by (18) F-FDG-PET, in healthy aging and AD, also considering the effects of education and occupation...
May 31, 2017: Human Brain Mapping
https://www.readbyqxmd.com/read/28560160/application-of-calibrated-fmri-in-alzheimer-s-disease
#17
Isabelle Lajoie, Scott Nugent, Clément Debacker, Kenneth Dyson, Felipe B Tancredi, AmanPreet Badhwar, Sylvie Belleville, Yan Deschaintre, Pierre Bellec, Julien Doyon, Christian Bocti, Serge Gauthier, Douglas Arnold, Marie-Jeanne Kergoat, Howard Chertkow, Oury Monchi, Richard D Hoge
Calibrated fMRI based on arterial spin-labeling (ASL) and blood oxygen-dependent contrast (BOLD), combined with periods of hypercapnia and hyperoxia, can provide information on cerebrovascular reactivity (CVR), resting blood flow (CBF), oxygen extraction fraction (OEF), and resting oxidative metabolism (CMRO2). Vascular and metabolic integrity are believed to be affected in Alzheimer's disease (AD), thus, the use of calibrated fMRI in AD may help understand the disease and monitor therapeutic responses in future clinical trials...
2017: NeuroImage: Clinical
https://www.readbyqxmd.com/read/28560150/amyloid-positron-emission-tomography-in-sporadic-cerebral-amyloid-angiopathy-a-systematic-critical-update
#18
REVIEW
Karim Farid, Andreas Charidimou, Jean-Claude Baron
Sporadic cerebral amyloid angiopathy (CAA) is a very common small vessel disease of the brain, showing preferential and progressive amyloid-βdeposition in the wall of small arterioles and capillaries of the leptomeninges and cerebral cortex. CAA now encompasses not only a specific cerebrovascular pathological trait, but also different clinical syndromes - including spontaneous lobar intracerebral haemorrhage (ICH), dementia and 'amyloid spells' - an expanding spectrum of brain parenchymal MRI lesions and a set of diagnostic criteria - the Boston criteria, which have resulted in increasingly detecting CAA during life...
2017: NeuroImage: Clinical
https://www.readbyqxmd.com/read/28559417/the-ftd-like-syndrome-causing-trem2-t66m-mutation-impairs-microglia-function-brain-perfusion-and-glucose-metabolism
#19
Gernot Kleinberger, Matthias Brendel, Eva Mracsko, Benedikt Wefers, Linda Groeneweg, Xianyuan Xiang, Carola Focke, Maximilian Deußing, Marc Suárez-Calvet, Fargol Mazaheri, Samira Parhizkar, Nadine Pettkus, Wolfgang Wurst, Regina Feederle, Peter Bartenstein, Thomas Mueggler, Thomas Arzberger, Irene Knuesel, Axel Rominger, Christian Haass
Genetic variants in the triggering receptor expressed on myeloid cells 2 (TREM2) increase the risk for several neurodegenerative diseases including Alzheimer's disease and frontotemporal dementia (FTD). Homozygous TREM2 missense mutations, such as p.T66M, lead to the FTD-like syndrome, but how they cause pathology is unknown. Using CRISPR/Cas9 genome editing, we generated a knock-in mouse model for the disease-associated Trem2 p.T66M mutation. Consistent with a loss-of-function mutation, we observe an intracellular accumulation of immature mutant Trem2 and reduced generation of soluble Trem2 similar to patients with the homozygous p...
May 30, 2017: EMBO Journal
https://www.readbyqxmd.com/read/28553176/metabolic-activity-value-in-the-posterior-cingulate-cortex-using-f-18-fluorodeoxyglucose-positron-emission-tomography-brain-to-predict-the-severity-of-alzheimer-s
#20
Aulia Huda, Achmad Hussein Sundawa Kartamihardja, Budi Darmawan, Hendra Budiawan, Martina Wiwie
Alzheimer's disease (AD) is a type of dementia which is known as one of a major problem in elderly. Clinicians commonly use mini-mental state examination (MMSE) score to determine the severity of cognitive decline, but MMSE has some limitations such as more subjective, influenced by age, educational degree, and local culture. F-18 fluorodeoxyglucose positron emission tomography (F-18 FDG PET) can be used to assess the process of glucose metabolism in posterior cingulate cortex (PCC) area which endures a central role in supporting cognitive function directly...
April 2017: World Journal of Nuclear Medicine
keyword
keyword
94283
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"